Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are
often diagnosed at a later stage and might receive less (intensive) treatment, which might …

Chemokines are chemotactic cytokines that promote cancer growth, metastasis, and
regulate resistance to chemotherapy. Stromal cell-derived factor 1 (SDF1) also known as …

Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC),
the median overall survival of both control and experimental arms has steadily improved …

Colorectal cancer is the third most common and the second deadliest cancer worldwide. To
date, colorectal cancer becomes one of the most important challenges of the health system …

Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal
evolution. Multiple genes and pathways have a role in tumor initiation and progression. The …

Mutations in RAS, BRAF, PIK3CA, and TP53 are well-established genetic abnormalities in
metastatic colorectal cancer (mCRC). However, limited information is available for patients …

Simple Summary The implementation of immunotherapy in the therapeutic landscape of
colorectal carcinoma has been difficult due to the inefficacy reported in early clinical trials …

Simple Summary The MAP kinases pathway has shown a key role in the pathogenesis of
colorectal cancer. The development of targeted therapy against BRAF-mutated tumors is …

BRAF mutated colon cancer presents with poor survival, and the treatment strategies are
controversial. The tumor microenvironment, which plays a key role in tumorigenesis as well …

Pancreatic neuroendocrine neoplasms (PanNENs) are the neuroendocrine neoplasms with
greatest rate of increase in incidence. Approximately 10% of PanNENs arise as inherited …